Selected article for: "acute respiratory distress and lung damage"
Author: Bonam, Srinivasa Reddy; Kaveri, Srini V.; Sakuntabhai, Anavaj; Gilardin, Laurent; Bayry, Jagadeesh
Title: Adjunct immunotherapies for the management of severely ill COVID-19 patients
  • Cord-id: 3uodkrkp
  • Document date: 2020_4_30
    • ID: 3uodkrkp
    Snippet: Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions with more than 181,000 fatal cases as of 22nd April 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and d
    Document: Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions with more than 181,000 fatal cases as of 22nd April 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation and passive viral neutralization, not only reduce inflammation, inflammation-associated lung damage, or viral load, but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation both of which are limited resources.

    Search related documents:
    Co phrase search for related documents
    • activate immune cell and acute respiratory syndrome: 1
    • activate immune cell and adaptive immune cell: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune cell: 1, 2
    • acute ards respiratory distress syndrome and additional target: 1
    • acute ards respiratory distress syndrome and adjunct therapy: 1, 2, 3
    • acute ards respiratory distress syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and long term survival: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immune cell: 1, 2
    • acute infection and additional immunotherapy: 1
    • acute infection and adjunct therapy: 1, 2, 3
    • acute infection and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute infection and local guideline: 1
    • acute infection and long term survival: 1, 2, 3, 4
    • acute infection and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and adaptive immune cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory and additional immunotherapy: 1
    • acute respiratory and additional possibility: 1, 2, 3, 4, 5
    • acute respiratory and additional target: 1, 2, 3, 4, 5